Gold prices steady with focus on Ukraine-Russia, Jackson Hole
Tuesday, Deutsche Bank (ETR:DBKGn) initiated coverage on Harmony Biosciences Holdings Inc. (NASDAQ: NASDAQ:HRMY), assigning a Buy rating and setting a price target of $55. The firm’s analysts highlighted HRMY’s successful commercial track record with its narcolepsy treatment, Wakix (pitolisant), noting five years of strong revenue growth and the potential to reach over $1 billion in peak sales before the loss of exclusivity (LOE) in 2030. The company’s impressive 25.83% revenue growth over the last twelve months and robust 78.65% gross profit margin support this optimistic outlook. According to InvestingPro analysis, HRMY is currently trading below its Fair Value, suggesting potential upside opportunity.
The management team at Harmony (JO:HARJ) Biosciences has been commended for effectively managing challenges that have previously weighed on the stock, such as a critical report from a short seller and a Phase 3 clinical trial miss for pitolisant in the treatment of idiopathic hypersomnia (IH). Deutsche Bank analysts underscored the company’s efforts to diversify revenue streams beyond Wakix through a multi-faceted growth strategy. They believe that the success of this strategy could lead to a re-evaluation of the company’s shares. InvestingPro data reveals two key strengths: the company holds more cash than debt on its balance sheet and maintains strong cash flows to cover interest payments. These are just 2 of 8 valuable ProTips available with an InvestingPro subscription.
The analysts anticipate that Harmony Biosciences could see a higher valuation multiple if the company manages to partially de-risk one or more assets in its pipeline in the near term. They pointed out that the current market valuation of HRMY, with a market cap of $2.17 billion and an EV/EBITDA ratio of 9.26, seems to reflect only its core Wakix business, with little consideration for its other pipeline projects. This perspective suggests an attractive risk-reward balance for the company as it approaches clinical and regulatory milestones over the next 12 to 18 months.
Deutsche Bank’s initiation of coverage and positive outlook for Harmony Biosciences comes at a time when the company is focused on expanding its product offerings and maintaining the momentum of its flagship product, Wakix. With a clear strategy in place, Harmony Biosciences aims to continue its trajectory of growth and potentially increase shareholder value as it navigates upcoming catalysts in its pipeline. For a comprehensive analysis of HRMY’s financial health, growth prospects, and detailed valuation metrics, investors can access the full Pro Research Report available exclusively on InvestingPro.
In other recent news, Harmony Biosciences reported significant revenue growth with its Q4 2024 net product revenues reaching approximately $201 million and full-year revenues amounting to around $714 million, indicating an approximate 23% increase from the previous year. The company also projects its 2025 net revenues to range between $820 to $860 million. H.C. Wainwright has maintained a positive stance on Harmony Biosciences, reaffirming a Buy rating and a $75.00 price target, highlighting the potential of the company’s narcolepsy drug WAKIX to generate over $1 billion in annual revenues by 2030.
In addition, Oppenheimer raised its price target on Harmony Biosciences stock to $61 from $59, while maintaining an Outperform rating, following the company’s strong Q4 2024 performance. Harmony’s late-stage pipeline includes treatments such as ZYN002, a cannabidiol gel, expected to produce Phase 3 top-line data in 2025, and EPX100 (clemizole hydrochloride), aimed at modulating serotonin signaling, projected to reach Phase 3 top-line data for Dravet syndrome in 2026.
These developments are part of Harmony Biosciences’ strategy to expand its neuroscience pipeline, which includes several potential catalysts expected throughout the year. Notably, Harmony Biosciences is awaiting a decision from the FDA on a supplemental New Drug Application for WAKIX in treating idiopathic hypersomnia, expected in the first quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.